{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:18:09Z","timestamp":1761675489584},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.cancergencyto.2007.03.002","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T14:11:17Z","timestamp":1182003077000},"page":"54-57","source":"Crossref","is-referenced-by-count":17,"title":["The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma"],"prefix":"10.1016","volume":"176","author":[{"given":"Meri-Sisko","family":"Vuoristo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2007.03.002_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/pr.55.2.4","article-title":"Interleukin-10 therapy \u2013 review of a new approach","volume":"55","author":"Asadullah","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2370.1997.tb00001.x","article-title":"An investigation of polymorphism in the interleukin-10 gene promoter","volume":"24","author":"Turner","year":"1997","journal-title":"Eur J Immunogenet"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0966-3274(98)80045-2","article-title":"Genotyping for polymorphisms in interferon-\u03b3, interleukin-10, transforming growth factor-\u00df1 and tumour necrosis factor-\u03b1 genes: a technical report","volume":"6","author":"Perrey","year":"1998","journal-title":"Transplant Immunol"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10689-005-0072-3","article-title":"Interleukin-10 polymorphisms, cancer susceptibility and prognosis","volume":"5","author":"Howell","year":"2006","journal-title":"Fam Cancer"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.gene.6363726","article-title":"IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma","volume":"2","author":"Howell","year":"2001","journal-title":"Genes Immunity"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00008390-200209000-00008","article-title":"Interleukin-10, interleukin-6 and interferon-(gamma) gene polymorphisms in melanoma patients","volume":"12","author":"Martinez-Escribano","year":"2002","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00008390-200502000-00009","article-title":"Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease","volume":"15","author":"Alonso","year":"2005","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1078-0432.1237.11.3","article-title":"Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study","volume":"11","author":"Liu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6","article-title":"Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus","volume":"41","author":"Mok","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.510300207","article-title":"Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alpha","volume":"30","author":"Edwards-Smith","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib12","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1084\/jem.180.6.2371","article-title":"Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression","volume":"180","author":"Matsuda","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E","article-title":"Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules","volume":"71","author":"Yue","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1081\/CNV-100102550","article-title":"Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanved melanoma","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"Cancer Invest"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/107999099313532","article-title":"Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience","volume":"19","author":"Huang","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cancergencyto.2007.03.002_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1529-8019.2005.00052.x","article-title":"Cutaneous melanoma: available therapy for metastatic disease","volume":"19","author":"Tarhini","year":"2006","journal-title":"Dermatol Ther"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460807001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460807001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:22:09Z","timestamp":1707967329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460807001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0165460807001288"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2007.03.002","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}